The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
July 11th 2025
States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.
FDA Approves Castration-Sensitive Prostate Cancer Drug
February 9th 2018Officials with the FDA have granted approval to abiraterone acetate (Zytiga) tablets in combination with prednisone for the treatment of metastatic high-risk castration-sensitive prostate cancer (CSPC), according to a press release.
Read More
Combination Therapy That Includes Daratumumab Lowers Risk of Multiple Myeloma Progression
February 9th 2018Study results show patients with newly diagnosed multiple myeloma showed a lower risk of disease progression or death with daratumumab added to the standard regimen of bortezomib, melphalan and prednisone, than patients who were treated without daratumumab in their drug combination.
Read More
FDA: Kratom Compounds Contain Opioid Properties
February 7th 2018In newly-released scientific analysis and data, the FDA has indicated strong evidence of the presence of compounds in kratom that strongly bind to opioid receptors, according to a statement released by FDA Commissioner Scott Gottlieb, MD.
Read More
ACIP Releases Revised 2018 Child and Adolescent Vaccine Schedule
February 7th 2018The updated 2018 immunization schedules for children and teens has been released by the Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP).
Read More
Opinion: A Reaction to DEA's Efforts to Target Pharmacies with 'Unusual' Opioid Prescription Rates
February 5th 2018Although it is unclear what constitutes “unusual or disproportionate,” such phrases are particularly disturbing when we realize that the regulation of medical practice is a traditional state function, not a federal one.
Read More
Combo Inhibitor Antibiotic Approved to Treat HABP/VABP
February 3rd 2018The US Food and Drug Administration has approved Allergan's supplemental New Drug Application to expand the approved use of their cephalosporin / beta-lactamase inhibitor combo antibiotic, AVYCAZ (ceftazidime and avibactam), to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms: Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenzae in patients 18 years of age or older.
Read More
Flu Hospitalizations Reach Record High as Activity Escalates
February 3rd 2018This year’s flu season is on track to exceed previous seasons of high severity in hospitalization rates as influenza activity and related deaths continue to climb across the United States, according to a CDC media briefing held today.
Read More